ArticleThe Journal of biological chemistry2026
Biosensor-guided discovery of peptide inhibitors targeting the ribosomal protein uS5-PDCD2 chaperone interaction.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed cell death 2 (PDCD2) is an evolutionarily conserved protein essential for cell viability from yeast to humans. PDCD2 functions as a dedicated chaperone to the 40S ribosomal protein uS5, and loss of PDCD2 function impairs ribosome biogenesis. As cancer cells require a substantial supply of ribosomes to maintain elevated levels of protein synthesis, targeting the protein interaction interface between PDCD2 and uS5 is a promising modality to mitigate ribosome biogenesis. In this study, we used affinity purification assays and structural modeling to identify a stretch of 30 amino acids in the N-terminal region of uS5 that is necessary and sufficient for interaction with PDCD2. Our data also identified a conserved FxxGFG motif in uS5 that is important for association with PDCD2 via hydrophobic interactions. Notably, we developed a sensitive complementation-based biosensor that can monitor PDCD2-uS5 interaction in cell extracts and living human cells. Using this biosensor, we identified an 11-amino acid uS5-derived peptide that inhibits the PDCD2-uS5 interaction and impairs cancer cell viability. Such peptides provide a starting point in the development of peptidomimetic inhibitors capable of modulating ribosome biogenesis via disruption of ribosomal protein-dedicated chaperone complexes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.